Clariane SE (EPA:CLARI)
France
· Delayed Price · Currency is EUR | Market Cap | 1.45B |
| Revenue (ttm) | 5.31B |
| Net Income (ttm) | 1.60M |
| Shares Out | 356.50M |
| EPS (ttm) | 0.00 |
| PE Ratio | 911.48 |
| Forward PE | 16.53 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 538,909 |
| Average Volume | 401,716 |
| Open | 4.090 |
| Previous Close | 4.100 |
| Day's Range | 4.000 - 4.130 |
| 52-Week Range | 3.270 - 5.505 |
| Beta | 0.76 |
| RSI | 64.89 |
| Earnings Date | Jul 29, 2026 |
About Clariane SE
Clariane SE provides care homes, healthcare facilities and services, and shared living solutions in France, Germany, Benelux, Italy, Spain, and the United Kingdom. It operates long-term care and short stay nursing homes. The company also provides inpatient and outpatient services, full-time hospitalization, day hospitalization, and outpatient care, and operates post-acute and rehabilitation care clinics, mental healthcare clinics, and medicine-surgery-obstetrics facilities. In addition, it offers medicalized nursing homes and alternative living... [Read more]
Financial Performance
Financial StatementsNews
Clariane SE Earnings Call Transcript: Q1 2026
Solid organic revenue growth of +4.9% in Q1 2026 was driven by improved occupancy, pricing, and strong performance across all segments and geographies. Liquidity was strengthened by a successful EUR 500 million bond issue, and medium-term guidance was confirmed.
Clariane SE Earnings Call Transcript: Q4 2025
Delivered strong 2025 results with 4.5% organic revenue growth, improved profitability, and reduced leverage. Strategic divestments, cost efficiency programs, and a robust outlook support continued margin and cash flow gains through 2028.
Clariane SE Earnings Call Transcript: Q3 2025
Q3 2025 saw accelerated organic revenue growth (+5.1%) and strong segment performance, with all geographies contributing. Financial structure was reinforced through early asset disposals and a €500M bond, while cost reduction measures ramp up more slowly, supporting margin improvement into 2026.
Clariane SE Earnings Call Transcript: Q2 2025
Solid H1 2025 results with 4.8% organic revenue growth, successful €1B asset disposal, and strengthened liquidity. Guidance for 6–9% EBITDA growth and leverage below 5.5x is confirmed, with margin recovery expected in H2 from pricing and operational improvements.
Clariane SE Transcript: AGM 2025
The meeting confirmed strong financial recovery, with sales up 6.6% and net profit returning to positive. Major governance changes included a new Chair and updated remuneration policies. All resolutions passed, and the group continues to focus on debt reduction, asset divestment, and climate adaptation.
Clariane SE Earnings Call Transcript: Q1 2025
Q1 2025 organic revenue grew 4.8% (5.5% ex-leap year), with all segments and regions contributing. Asset disposals reached €600 million, targeting €1 billion by end-2025, and 2025 guidance for revenue and EBITDA growth is confirmed. HoldCo leverage is set to fall below 5.5x.
Clariane SE Earnings Call Transcript: Q4 2024
Solid organic revenue growth of 6.6% and improved operating margin marked a recovery year, with €409 million debt reduction and 50% of the €1 billion asset disposal plan completed. 2025 guidance targets 5% sales growth, 6–9% EBITDA growth, and further deleveraging.
Clariane SE Earnings Call Transcript: Q3 2024
Organic revenue grew 6.3% in the first nine months of 2024, driven by both price and volume, with all segments and regions contributing. Asset disposals progressed, supporting liquidity for upcoming maturities, and 2024 guidance for >5% organic growth and stable EBITDA was reaffirmed.
Clariane SE Earnings Call Transcript: H1 2024
Revenue grew 6.8% organically in H1 2024, with EBITDA and cash flow improving and net debt reduced by EUR 500 million. Asset disposals and refinancing progressed, outlook reaffirmed, and new build program scaled back to 2,700 pre-financed beds.